RxDoctor Payments Data

Isaac Mohr, PA

Medical · Lancaster, PANPI 1346724820

Payments from drug & device makers

$2,962in general payments, 2019–2025

Across 122 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$495
  • Teleflex LLC$438
  • AstraZeneca$309
  • Urovant Sciences Inc$190
  • Pfizer$139
  • Procept Biorobotics Corporation$133
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,83296%
  • Education$1304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,962 in reported general payments places this provider in the 80th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$18,607
Medicare patients
165
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron97$56,995
GemtesaVibegron34$17,354
Tamsulosin Hcl210$2,883
Finasteride211$1,979
Trospium Chloride35$1,495
Dutasteride18$1,449
Methenamine Hippurate14$1,244
Solifenacin Succinate23$1,145
Cefpodoxime Proxetil41$1,121
Alfuzosin Hcl ErAlfuzosin Hcl44$920
Tadalafil11$777
Oxybutynin Chloride ErOxybutynin Chloride27$342
NitrofurantoinNitrofurantoin Macrocrystal24$333
Oxybutynin Chloride21$327
Levofloxacin32$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$495$56,99597 claims
Sumitomo Pharma America, Inc.Gemtesa$59$17,35434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →